



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 54**

(48) Corrigendum issued on:  
**02.06.2021 Bulletin 2021/22**

(45) Date of publication and mention  
of the grant of the patent:  
**07.04.2021 Bulletin 2021/14**

(21) Application number: **16753597.0**

(22) Date of filing: **27.07.2016**

(51) Int Cl.:  
**A61K 45/06** <sup>(2006.01)</sup> **A61K 31/337** <sup>(2006.01)</sup>  
**A61K 31/517** <sup>(2006.01)</sup> **A61K 33/24** <sup>(2019.01)</sup>  
**A61P 35/00** <sup>(2006.01)</sup> **A61K 31/7068** <sup>(2006.01)</sup>  
**A61K 33/243** <sup>(2019.01)</sup> **C12Q 1/6886** <sup>(2018.01)</sup>  
**G01N 33/574** <sup>(2006.01)</sup> **A61K 39/395** <sup>(2006.01)</sup>  
**C07K 16/32** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/EP2016/067892**

(87) International publication number:  
**WO 2017/017133 (02.02.2017 Gazette 2017/05)**

(54) **TREATMENT OF PATIENTS DIAGNOSED WITH PANCREATIC DUCTAL ADENOCARCINOMA  
USING MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR  
(EGFR)**

BEHANDLUNG VON PATIENTEN MIT DIAGNOSTIZIERTEM DUKTALEN ADENOKARZINOM DES  
PANKREAS MIT MONOKLONALEN ANTIKÖRPERN GEGEN DEN EPIDERMALLEN  
WACHSTUMSFAKTOR REZEPTOR (EGFR)

TRAITEMENT DES PATIENTS DIAGNOSTIQUÉS AVEC UN ADÉNOCARCINOME CANALAIRE PAR  
DES ANTICORPS MONOCLONAUX CONTRE LE RECEPTEUR DU FACTEUR DE CROISSANCE  
ÉPIDERMIQUE

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO RS SE SI SK SM TR**

(30) Priority: **27.07.2015 EP 15178489**

(43) Date of publication of application:  
**06.06.2018 Bulletin 2018/23**

(73) Proprietors:  
• **InnoCIMA b Pte Ltd**  
**Singapore 659065 (SG)**  
• **Oncoscience AG**  
**22880 Wedel (DE)**

(72) Inventors:  
• **STRUMBERG, Dirk**  
**44621 Herne (DE)**  
• **SCHULTHEIS, Beate**  
**Herne (DE)**

- **EBERT, Matthias, P.**  
**Munich (DE)**
- **SIVEKE, Jens**  
**Munich (DE)**
- **KERKHOFF, Andrea**  
**Muenster (DE)**
- **HOFHEINZ, Ralf**  
**Mannheim (DE)**
- **BEHRINGER, Dirk, M.**  
**Bochum (DE)**
- **SCHMIDT, Wolfgang, E.**  
**Bochum (DE)**
- **GOKER, Erdem**  
**Izmir (TR)**
- **DE DOSSO, Sara**  
**Bellinzona (CH)**
- **KNEBA, Michael**  
**Kiel (DE)**
- **YALCIN, Suayib**  
**Ankara (TR)**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- OVERKAMP, Friedrich  
Recklinghausen (DE)
- SCHLEGEL, Frank  
Eschweiler (DE)
- DOMMACH, Markus  
Duesseldorf (DE)
- ROHRBERG, Robert  
Halle (DE)
- STEINMETZ, Tilman  
Cologne (DE)
- BACH, Ferdinand  
22880 Wedel (DE)
- REUTER, Dirk  
22880 Wedel (DE)
- ILYAS, Rikrik, Asiyah  
Singapore 658065 (SG)
- IZNAGA ESCOBAR, Normando, E.  
Singapore 658065 (SG)

(74) Representative: **Schiweck Weinzierl Koch  
Patentanwälte Partnerschaft mbB  
Ganghoferstraße 68 B  
80339 München (DE)**

(56) References cited:

EP-A1- 2 070 547 WO-A1-2013/138371  
WO-A1-2014/095766

- Sideways: "EGFR inhibition is effective against KRAS-wild-type disease | Nature Reviews Clinical Oncology", Nature reviews clinical oncology, 25 July 2017 (2017-07-25), XP55536776, Retrieved from the Internet: URL:<https://www.nature.com/articles/nrclinonc.2017.119> [retrieved on 2018-12-19]
- B. SCHULTHEIS ET AL: "Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study", ANNALS OF ONCOLOGY., vol. 28, no. 10, 6 July 2017 (2017-07-06), pages 2429-2435, XP055652203, NL ISSN: 0923-7534, DOI: 10.1093/annonc/mdx343